Production (Stage)
Fresh Tracks Therapeutics, Inc.
FRTX
OTC PK
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | 14,888.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | 14,888.68% | |||
| Cost of Revenue | -98.41% | 2.96% | |||
| Gross Profit | -100.14% | 1,416.01% | |||
| SG&A Expenses | -69.14% | 194.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -72.22% | 146.05% | |||
| Operating Income | -182.72% | 184.48% | |||
| Income Before Tax | -158.84% | 192.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -158.84% | 192.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -164.92% | 183.49% | |||
| EBIT | -182.72% | 184.48% | |||
| EBITDA | -181.77% | 185.30% | |||
| EPS Basic | -164.22% | 183.40% | |||
| Normalized Basic EPS | -168.43% | 178.24% | |||
| EPS Diluted | -164.22% | 183.40% | |||
| Normalized Diluted EPS | -168.43% | 178.24% | |||
| Average Basic Shares Outstanding | 1.11% | 0.11% | |||
| Average Diluted Shares Outstanding | 1.11% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||